Website
N/ATelephone
N/A
Address
Description
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in Adelaide, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.05
Trade Value (12mth)
AU$1,409.00
1 week
0%
1 month
-6.79%
YTD
-0.58%
1 year
-21.51%
All time high
1.66427
EPS 3 yr Growth
-70.400%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-193.50%
ROIC
-173.40%
Interest Coverage
-1,375.60
Quick Ratio
2.90
Shares on Issue (Fully Dilluted)
128m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Appendix 4C & Q1 FY24 Activities Report
×
Appendix 4C & Q1 FY24 Activities Report |
31 October 22 |
Entitlement Offer Letter to Shareholders
×
Entitlement Offer Letter to Shareholders |
31 October 22 |
Change in substantial holding from TEK
×
Change in substantial holding from TEK |
31 October 22 |
Change in substantial holding - Tiga Trading Pty Ltd
×
Change in substantial holding - Tiga Trading Pty Ltd |
31 March 22 |
Clinical Trials Update
×
Clinical Trials Update |
31 July 23 |
Appendix 4C & Q4 FY23 Activities Report
×
Appendix 4C & Q4 FY23 Activities Report |
31 August 23 |
IBS clinical trial Stage 1 patients finalised
×
IBS clinical trial Stage 1 patients finalised |
30 November 22 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
30 January 23 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
29 September 21 |
Annual General Meeting & Director Nominations
×
Annual General Meeting & Director Nominations |
29 September 17 |
Annual Report 2017
×
Annual Report 2017 |
29 October 20 |
Investor Presentation
×
Investor Presentation |
29 July 22 |
Quarterly Appendix 4C Cash Flow Report
×
Quarterly Appendix 4C Cash Flow Report |
29 August 22 |
Appendix 4E & Audited Financial Report 30 June 2022
×
Appendix 4E & Audited Financial Report 30 June 2022 |
29 April 22 |
Appendix 4C and Q3 FY22 Activities Report
×
Appendix 4C and Q3 FY22 Activities Report |
28 September 23 |
ANR announces Positive Results from Stage 1 of IBS trial
×
ANR announces Positive Results from Stage 1 of IBS trial |
28 October 22 |
Appendix 4C & Q1 FY23 Activities Report
×
Appendix 4C & Q1 FY23 Activities Report |
28 October 22 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
28 October 22 |
Cleansing Notice
×
Cleansing Notice |
28 November 22 |
Application for quotation of securities - ANR
×
Application for quotation of securities - ANR |
28 November 22 |
Notification regarding unquoted securities - ANR
×
Notification regarding unquoted securities - ANR |
28 November 19 |
Anatara Investor Presentation and Update
×
Anatara Investor Presentation and Update |
28 March 23 |
Change in substantial holding
×
Change in substantial holding |
28 January 22 |
Appendix 4C and Q2 FY22 Activities Report
×
Appendix 4C and Q2 FY22 Activities Report |
27 October 20 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 October 20 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
27 January 22 |
Appendix 4C and Q2 FY22 Activities Report
×
Appendix 4C and Q2 FY22 Activities Report |
26 September 23 |
Pause in Trading
×
Pause in Trading |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.